- Home
- PRVA vs APGE Comparison
PRVA vs APGE Comparison
Compare PRVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- APGE
- Stock Information
- Founded
- PRVA 2007
- APGE 2022
- Country
- PRVA United States
- APGE United States
- Employees
- PRVA N/A
- APGE N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRVA Technology
- APGE Health Care
- Exchange
- PRVA Nasdaq
- APGE Nasdaq
- Market Cap
- PRVA 2.7B
- APGE 2.1B
- IPO Year
- PRVA 2021
- APGE 2023
- Fundamental
- Price
- PRVA $21.92
- APGE $44.32
- Analyst Decision
- PRVA Strong Buy
- APGE Strong Buy
- Analyst Count
- PRVA 14
- APGE 4
- Target Price
- PRVA $27.93
- APGE $97.50
- AVG Volume (30 Days)
- PRVA 1.0M
- APGE 913.3K
- Earning Date
- PRVA 08-07-2025
- APGE 08-11-2025
- Dividend Yield
- PRVA N/A
- APGE N/A
- EPS Growth
- PRVA N/A
- APGE N/A
- EPS
- PRVA 0.12
- APGE N/A
- Revenue
- PRVA $1,801,244,000.00
- APGE N/A
- Revenue This Year
- PRVA $90.63
- APGE N/A
- Revenue Next Year
- PRVA $10.51
- APGE $743.14
- P/E Ratio
- PRVA $181.82
- APGE N/A
- Revenue Growth
- PRVA 6.79
- APGE N/A
- 52 Week Low
- PRVA $16.47
- APGE $26.20
- 52 Week High
- PRVA $26.09
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- PRVA 42.45
- APGE 61.88
- Support Level
- PRVA $21.55
- APGE $42.88
- Resistance Level
- PRVA $23.15
- APGE $44.61
- Average True Range (ATR)
- PRVA 0.74
- APGE 2.37
- MACD
- PRVA 0.04
- APGE 0.12
- Stochastic Oscillator
- PRVA 25.27
- APGE 63.45
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.